Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Br J Radiol. 2023 Sep;96(1149):20221153. doi: 10.1259/bjr.20221153. Epub 2023 Apr 26.
Breast cancer is the most common cancer in females worldwide. Nuclear medicine plays an important role in patient management, not only in initial staging, but also during follow-up. Radiopharmaceuticals to study breast cancer have been used for over 50 years, and several of these are still used in clinical practice, according to the most recent guideline recommendations.In this critical review, an overview of nuclear medicine procedures used during the last decades is presented. Current clinical indications of each of the conventional nuclear medicine and PET/CT examinations are the focus of this review, and are objectively provided. Radionuclide therapies are also referred, mainly summarising the methods to palliate metastatic bone pain. Finally, recent developments and future perspectives in the field of nuclear medicine are discussed. In this context, the promising potential of new radiopharmaceuticals not only for diagnosis, but also for therapy, and the use of quantitative imaging features as potential biomarkers, are addressed.Despite the long way nuclear medicine has gone through, it looks like it will continue to benefit clinical practice, paving the way to improve healthcare provided to patients with breast cancer.
乳腺癌是全球女性最常见的癌症。核医学在患者管理中发挥着重要作用，不仅在初始分期，而且在随访期间也是如此。根据最新的指南建议，用于研究乳腺癌的放射性药物已经使用了 50 多年，其中一些仍在临床实践中使用。在这篇重要的综述中，介绍了过去几十年中使用的核医学程序的概述。本次回顾的重点是每一种常规核医学和 PET/CT 检查的当前临床适应证，并客观地提供了这些适应证。放射性核素治疗也被提及，主要总结了缓解转移性骨痛的方法。最后，讨论了核医学领域的最新进展和未来展望。在这方面，探讨了新放射性药物不仅在诊断而且在治疗方面的有前途的潜力，以及将定量成像特征用作潜在的生物标志物的应用。尽管核医学已经走过了漫长的道路，但它似乎将继续有益于临床实践，为改善乳腺癌患者的医疗服务铺平道路。
